Cullinan Oncology (CGEM) News Today → Bible Shocker: Have You Seen Elon Musk’s Miracle? (From InvestorPlace) (Ad) Free CGEM Stock Alerts $23.17 -0.64 (-2.69%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 19 at 12:00 AM | uk.investing.comCullinan Oncology stock target trimmed, maintains Buy ratingMay 18 at 5:36 AM | americanbankingnews.comHC Wainwright Lowers Cullinan Oncology (NASDAQ:CGEM) Price Target to $28.00May 17 at 2:12 AM | americanbankingnews.comCullinan Oncology (NASDAQ:CGEM) Stock Price Down 6.6% After Analyst DowngradeMay 16 at 7:41 PM | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 16 at 7:41 PM | markets.businessinsider.comBuy Rating Affirmed for Cullinan Management Ahead of Key ASCO Presentation and Strong FinancialsMay 16 at 12:56 PM | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Shares Down 6.6% After Analyst DowngradeCullinan Oncology (NASDAQ:CGEM) Shares Down 6.6% Following Analyst DowngradeMay 16 at 12:39 PM | marketbeat.comHC Wainwright Trims Cullinan Oncology (NASDAQ:CGEM) Target Price to $28.00HC Wainwright dropped their target price on Cullinan Oncology from $29.00 to $28.00 and set a "buy" rating for the company in a report on Thursday.May 16 at 9:50 AM | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Rating Reiterated by WedbushWedbush restated an "outperform" rating and set a $36.00 price target on shares of Cullinan Oncology in a report on Thursday.May 16 at 9:40 AM | markets.businessinsider.comBuy Rating on Cullinan Management: Promising Pipeline and Strategic Pivot to AutoimmunityMay 16 at 12:06 AM | investorplace.comCGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024May 15, 2024 | globenewswire.comCullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 13, 2024 | marketbeat.comShort Interest in Cullinan Oncology, Inc. (NASDAQ:CGEM) Grows By 40.5%Cullinan Oncology, Inc. (NASDAQ:CGEM - Get Free Report) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,360,000 shares, an increase of 40.5% from the April 15th total of 1,680,000 shares. Based on an average trading volume of 711,900 shares, the days-to-cover ratio is currently 3.3 days. Approximately 10.2% of the company's shares are sold short.May 12, 2024 | americanbankingnews.comCullinan Oncology, Inc. (NASDAQ:CGEM) Given Average Recommendation of "Buy" by AnalystsMay 10, 2024 | insidertrades.comJennifer Michaelson Sells 58,000 Shares of Cullinan Oncology, Inc. (NASDAQ:CGEM) StockMay 9, 2024 | finance.yahoo.comInsider Sale at Cullinan Therapeutics Inc (CGEM): Chief Scientific Officer Jennifer Michaelson ...May 8, 2024 | marketbeat.comCullinan Oncology, Inc. (NASDAQ:CGEM) Insider Sells $1,628,060.00 in StockCullinan Oncology, Inc. (NASDAQ:CGEM - Get Free Report) insider Jennifer Michaelson sold 58,000 shares of Cullinan Oncology stock in a transaction on Monday, May 6th. The shares were sold at an average price of $28.07, for a total transaction of $1,628,060.00. Following the completion of the transaction, the insider now directly owns 129,582 shares of the company's stock, valued at approximately $3,637,366.74. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.May 3, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Reaches New 1-Year High at $29.25Cullinan Oncology (NASDAQ:CGEM) Reaches New 52-Week High at $29.25May 1, 2024 | markets.businessinsider.comBuy Rating Justified: Cullinan Management’s Promising TCE Therapy Paves the Way for Market DominanceMay 1, 2024 | msn.comStifel Initiates Coverage of Cullinan Therapeutics (CGEM) with Buy RecommendationMay 1, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Now Covered by Analysts at Stifel NicolausStifel Nicolaus started coverage on Cullinan Oncology in a research note on Wednesday. They issued a "buy" rating and a $40.00 target price for the company.April 29, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Sees Unusually-High Trading VolumeCullinan Oncology (NASDAQ:CGEM) Sees Strong Trading VolumeApril 29, 2024 | globenewswire.comCullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial OfficerApril 26, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Reaches New 1-Year High at $21.89Cullinan Oncology (NASDAQ:CGEM) Reaches New 12-Month High at $21.89April 24, 2024 | finance.yahoo.comWhy Is Cullinan Therapeutics Stock Trading Higher On Wednesday?April 24, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Trading Up 7.8%Cullinan Oncology (NASDAQ:CGEM) Trading 7.8% HigherApril 24, 2024 | globenewswire.comCullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024April 19, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Trading Down 3.3%Cullinan Oncology (NASDAQ:CGEM) Stock Price Down 3.3%April 19, 2024 | marketbeat.comQ2 2024 EPS Estimates for Cullinan Oncology, Inc. (NASDAQ:CGEM) Raised by AnalystCullinan Oncology, Inc. (NASDAQ:CGEM - Free Report) - Stock analysts at William Blair increased their Q2 2024 EPS estimates for Cullinan Oncology in a research report issued on Tuesday, April 16th. William Blair analyst M. Phipps now anticipates that the company will post earnings of ($0.75) perApril 18, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Stock Price Up 5.9% After Analyst UpgradeCullinan Oncology (NASDAQ:CGEM) Shares Up 5.9% Following Analyst UpgradeApril 18, 2024 | marketbeat.comJonestrading Boosts Cullinan Oncology (NASDAQ:CGEM) Price Target to $26.00Jonestrading raised their price target on Cullinan Oncology from $22.00 to $26.00 and gave the company a "buy" rating in a report on Wednesday.April 18, 2024 | marketbeat.comHC Wainwright Weighs in on Cullinan Oncology, Inc.'s Q2 2024 Earnings (NASDAQ:CGEM)Cullinan Oncology, Inc. (NASDAQ:CGEM - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2024 EPS estimates for Cullinan Oncology in a note issued to investors on Tuesday, April 16th. HC Wainwright analyst E. White now forecasts that the company will earn ($0.67) per share for the quApril 17, 2024 | marketbeat.comWilliam Blair Comments on Cullinan Oncology, Inc.'s Q1 2024 Earnings (NASDAQ:CGEM)Cullinan Oncology, Inc. (NASDAQ:CGEM - Free Report) - Stock analysts at William Blair issued their Q1 2024 earnings per share estimates for shares of Cullinan Oncology in a research report issued on Monday, April 15th. William Blair analyst M. Phipps forecasts that the company will earn ($0.92) pApril 17, 2024 | marketbeat.comCullinan Oncology, Inc. (NASDAQ:CGEM) Receives Average Rating of "Buy" from BrokeragesShares of Cullinan Oncology, Inc. (NASDAQ:CGEM - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six ratings firms that are currently covering the firm, MarketBeat reports. Six analysts have rated the stock with a buy recommendation. The average 1 year target priceApril 17, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) PT Raised to $30.00BTIG Research boosted their price objective on Cullinan Oncology from $20.00 to $30.00 and gave the stock a "buy" rating in a research report on Wednesday.April 17, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $17.32Cullinan Oncology (NASDAQ:CGEM) Shares Gap Up to $17.32April 17, 2024 | finanznachrichten.deCullinan Therapeutics, Inc.: Cullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesApril 16, 2024 | markets.businessinsider.comBuy Recommendation: Cullinan Management’s Strategic Position in Autoimmune Disease Market with Promising CLN-978 TherapyApril 16, 2024 | bizjournals.comCullinan rebrands with $280M private offering, pivot away from cancerApril 16, 2024 | finance.yahoo.comCullinan changes name, pivots to autoimmune diseaseApril 16, 2024 | markets.businessinsider.comCullinan To Expand Into Autoimmune Diseases, Privately Places $280 Mln; Stock Up In Pre-MarketApril 16, 2024 | markets.businessinsider.comCullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via EquityApril 16, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Price Target Lowered to $29.00 at HC WainwrightHC Wainwright reduced their target price on shares of Cullinan Oncology from $34.00 to $29.00 and set a "buy" rating on the stock in a research report on Tuesday.April 16, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Hits New 52-Week High at $20.62Cullinan Oncology (NASDAQ:CGEM) Hits New 1-Year High at $20.62April 16, 2024 | marketwatch.comCullinan Oncology Shares Jump 21% on Planned Autoimmune Diseases Expansion, Private PlacementApril 16, 2024 | msn.comWilliam Blair Initiates Coverage of Cullinan Oncology (CGEM) with Outperform RecommendationApril 16, 2024 | globenewswire.comCullinan Therapeutics Announces Strategic Expansion into Autoimmune DiseasesApril 16, 2024 | globenewswire.comCullinan Therapeutics Announces Oversubscribed $280 million Private PlacementApril 15, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Coverage Initiated at William BlairWilliam Blair began coverage on Cullinan Oncology in a research report on Monday. They set an "outperform" rating for the company.April 12, 2024 | marketbeat.comCullinan Oncology, Inc. (NASDAQ:CGEM) Short Interest Up 53.9% in MarchCullinan Oncology, Inc. (NASDAQ:CGEM - Get Free Report) saw a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,440,000 shares, an increase of 53.9% from the March 15th total of 935,400 shares. Approximately 5.5% of the shares of the stock are short sold. Based on an average trading volume of 423,600 shares, the short-interest ratio is presently 3.4 days.April 8, 2024 | marketbeat.comCullinan Oncology (NASDAQ:CGEM) Shares Gap Down to $17.02Cullinan Oncology (NASDAQ:CGEM) Shares Gap Down to $17.02 Get Cullinan Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Bible Shocker: Have You Seen Elon Musk’s Miracle? (Ad)Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process. Click here for the full story… CGEM Media Mentions By Week CGEM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CGEM News Sentiment▼0.570.42▲Average Medical News Sentiment CGEM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CGEM Articles This Week▼152▲CGEM Articles Average Week Get Cullinan Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CGEM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: SRRK News BCRX News AUTL News XNCR News IMTX News PROK News FDMT News VIR News RLAY News TARS News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CGEM) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBill Gates is all about this tiny $2 stockTimothy SykesCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingDems have chosen Biden replacement?Paradigm PressMan who spotted Apple at $1.49 says: “Buy These 6 AI Stocks.”InvestorPlaceForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the Markets[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsBuy this small stock before coming AI Tidal WaveChaikin AnalyticsShocking $16T Elon Musk Crypto LeakCrypto 101 Media Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cullinan Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
